You are viewing the site in preview mode

Skip to main content

Advertisement

Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD

Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.

Page 1 of 2

  1. Content type: Research article

    Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinica...

    Authors: Mathieu Grapin, Corentin Richard, Emeric Limagne, Romain Boidot, Véronique Morgand, Aurélie Bertaut, Valentin Derangere, Pierre-Antoine Laurent, Marion Thibaudin, Jean David Fumet, Gilles Crehange, François Ghiringhelli and Céline Mirjolet

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:160

    Published on:

  2. Content type: Research article

    Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) in the tumor microenvironment i...

    Authors: Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, Wei Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou and Kebin Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:157

    Published on:

  3. Content type: Short report

    PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients w...

    Authors: William Damsky, Lucia Jilaveanu, Noel Turner, Curtis Perry, Christopher Zito, Mary Tomayko, Jonathan Leventhal, Kevan Herold, Eric Meffre, Marcus Bosenberg and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:153

    Published on:

  4. Content type: Research article

    T-cell mediated immunotherapy brought clinical success for many cancer patients. Nonetheless, downregulation of MHC class I antigen presentation, frequently occurring in solid cancers, limits the efficacy of t...

    Authors: Koen A. Marijt, Marjolein Sluijter, Laura Blijleven, Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg and Thorbald van Hall

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:152

    Published on:

  5. Content type: Research article

    Binding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory signals that promote exhaustion of activated T cells. Blockade of the PD-1 pathway is widely used for cancer tre...

    Authors: Jesús Ogando, María Eugenia Sáez, Javier Santos, Cristina Nuevo-Tapioles, Marta Gut, Anna Esteve-Codina, Simon Heath, Antonio González-Pérez, José M. Cuezva, Rosa Ana Lacalle and Santos Mañes

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:151

    Published on:

  6. Content type: Research article

    Tumor-associated macrophages (TAMs) are the major component of tumor-infiltrating immune cells. Macrophages are broadly categorized as M1 or M2 types, and TAMs have been shown to express an M2-like phenotype. ...

    Authors: Chanju Lee, Hyunju Jeong, Younghyeon Bae, Kyungmoon Shin, Sinwoo Kang, Hwikyung Kim, Jayoung Oh and Hyunsu Bae

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:147

    Published on:

  7. Content type: Research article

    Tumor-associated macrophages (TAM) are expanded and exhibit tumor-promoting properties within the tumor microenvironment. Current methods to study TAM have not been replicated across cancer types and often do ...

    Authors: Brooke Benner, Luke Scarberry, Lorena P. Suarez-Kelly, Megan C. Duggan, Amanda R. Campbell, Emily Smith, Gabriella Lapurga, Kallie Jiang, Jonathan P. Butchar, Susheela Tridandapani, John Harrison Howard, Robert A. Baiocchi, Thomas A. Mace and William E. Carson III

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:140

    Published on:

  8. Content type: Research article

    Targeting epitopes derived from neo-antigens (or “neo-epitopes”) represents a promising immunotherapy approach with limited off-target effects. However, most peptides predicted using MHC binding prediction alg...

    Authors: Hanan Besser, Sharon Yunger, Efrat Merhavi-Shoham, Cyrille J. Cohen and Yoram Louzoun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:135

    Published on:

  9. Content type: Short report

    High-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially co...

    Authors: Sonia Domingos-Pereira, Gabriele Galliverti, Douglas Hanahan and Denise Nardelli-Haefliger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:122

    Published on:

  10. Content type: Research article

    Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human disease was used to test...

    Authors: Weiqing Jing, Donna McAllister, Emily P. Vonderhaar, Katie Palen, Matthew J. Riese, Jill Gershan, Bryon D. Johnson and Michael B. Dwinell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:115

    Published on:

  11. Content type: Research article

    Induction of strong T cell responses, in particular cytotoxic T cells, is a key for the generation of efficacious therapeutic cancer vaccines which yet, remains a major challenge for the vaccine developing wor...

    Authors: Mona O. Mohsen, Matthew D. Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Marcos Sande, Jens V. Stein, Carsten Riether, Elisa Roesti, Lisha Zha, Paul Engeroff, Aadil El-Turabi, Thomas M. Kundig, Monique Vogel, Murray A. Skinner, Daniel E. Speiser…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:114

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:137

  12. Content type: Research article

    Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance...

    Authors: Marjolaine Debant, Miguel Burgos, Patrice Hemon, Paul Buscaglia, Tinhinane Fali, Sarra Melayah, Nelig Le Goux, Christophe Vandier, Marie Potier-Cartereau, Jacques-Olivier Pers, Adrian Tempescul, Christian Berthou, Cristina Bagacean, Olivier Mignen and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:111

    Published on:

  13. Content type: Research article

    The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies...

    Authors: Stefanie K. Wculek, Joaquín Amores-Iniesta, Ruth Conde-Garrosa, Sofía C. Khouili, Ignacio Melero and David Sancho

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:100

    Published on:

  14. Content type: Research article

    Notch intercellular communication instructs tissue-specific T-cell development and function. In this study, we explored the roles of dendritic cell (DC)-expressed Notch ligands in the regulation of T-cell effe...

    Authors: Elena E. Tchekneva, Mounika U.L. Goruganthu, Roman V. Uzhachenko, Portia L. Thomas, Anneliese Antonucci, Irina Chekneva, Michael Koenig, Longzhu Piao, Anwari Akhter, Maria Teresa P. de Aquino, Parvathi Ranganathan, Nicholas Long, Thomas Magliery, Anna Valujskikh, Jason V. Evans, Rajeswara R. Arasada…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:95

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:124

  15. Content type: Research article

    Low availability of oxygen in tumors contributes to the hostility of the tumor microenvironment toward the immune system. However, the dynamic relationship between local oxygen levels and the immune surveillan...

    Authors: Mateusz Rytelewski, Karine Haryutyunan, Felix Nwajei, Meenakshi Shanmugasundaram, Patrick Wspanialy, M. Anna Zal, Chao-Hsien Chen, Mirna El Khatib, Shane Plunkett, Sergei A. Vinogradov, Marina Konopleva and Tomasz Zal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:78

    Published on:

  16. Content type: Short report

    Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sough...

    Authors: Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J. Philip, Jo Ann Hsu, Nazli Dizman, Ulka Vaishampayan, Tanya Dorff and Sumanta Kumar Pal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:71

    Published on:

  17. Content type: Research article

    Tumor progression is accompanied by dramatic remodeling of the surrounding extracellular matrix leading to the formation of a tumor-specific ECM, which is often more collagen-rich and of increased stiffness. T...

    Authors: Dorota E. Kuczek, Anne Mette H. Larsen, Marie-Louise Thorseth, Marco Carretta, Adrija Kalvisa, Majken S. Siersbæk, Ana Micaela C. Simões, Anne Roslind, Lars H. Engelholm, Elfriede Noessner, Marco Donia, Inge Marie Svane, Per thor Straten, Lars Grøntved and Daniel H. Madsen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:68

    Published on:

  18. Content type: Research article

    Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human pati...

    Authors: E. Dodagatta-Marri, D. S. Meyer, M. Q. Reeves, R. Paniagua, M. D. To, M. Binnewies, M. L. Broz, H. Mori, D. Wu, M. Adoumie, R. Del Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:62

    Published on:

  19. Content type: Research article

    Immunogenic radiotherapy (RT) can act synergistically with immune checkpoint blockers (ICBs). However, alternatives are needed for non-responding patients and those with pre-existing or ICB-induced autoimmune ...

    Authors: Hua Jing, Michael Hettich, Simone Gaedicke, Elke Firat, Mark Bartholomä and Gabriele Niedermann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:55

    Published on:

  20. Content type: Research article

    Mast cells are prominent components of solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the nature, regulation, function, and clinical relevance of mast cells in huma...

    Authors: Yipin Lv, Yongliang Zhao, Xianhua Wang, Na Chen, Fangyuan Mao, Yongsheng Teng, Tingting Wang, Liusheng Peng, Jinyu Zhang, Ping Cheng, Yugang Liu, Hui Kong, Weisan Chen, Chuanjie Hao, Bin Han, Qiang Ma…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:54

    Published on:

  21. Content type: Research article

    The development of memory responses is an evolutionary function of the adaptive immune system. We propose that for the immune system to populate the memory compartment with the best-suited CD8 T cells it utili...

    Authors: Cynthia Perez, Kushal Prajapati, Brianna Burke, Lourdes Plaza-Rojas, Nancy J. Zeleznik-Le and Jose A. Guevara-Patino

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:48

    Published on:

  22. Content type: Research article

    The thymic stromal lymphopoietin (TSLP), a key cytokine for development of Th2 immunity, is produced by cancer associated fibroblasts (CAFs) in pancreatic cancer where predominant tumor infiltrating Th2 over T...

    Authors: Emanuela Brunetto, Lucia De Monte, Gianpaolo Balzano, Barbara Camisa, Vincenzo Laino, Michela Riba, Silvia Heltai, Marco Bianchi, Claudio Bordignon, Massimo Falconi, Attilio Bondanza, Claudio Doglioni and Maria Pia Protti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:45

    Published on:

  23. Content type: Research article

    Cervical cancer (CxCa) is mainly a locally invading disease that metastasizes to loco-regional lymph node basins before involving distant organs in more advanced stages. Local immune potentiation of tumor-drai...

    Authors: A. M. Heeren, J. Rotman, A. G. M. Stam, N. Pocorni, A. A. Gassama, S. Samuels, M. C. G. Bleeker, C. H. Mom, H. J. M. A. A. Zijlmans, G. G. Kenter, E. S. Jordanova and T. D. de Gruijl

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:43

    Published on:

  24. Content type: Research article

    The role of programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) in triple negative breast cancer (TNBC) remains to be fully understood. In this study, we investigated the role of PD-1...

    Authors: Joe Yeong, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Clara Chong Hui Ong, Aye Aye Thike, Wei Hseun Yeap, Yi Yang, Ansel Yi Herh Lim, Timothy Kwang Yong Tay, Jin Liu, Siew-Cheng Wong, Jinmiao Chen, Elaine Hsuen Lim, Jabed Iqbal, Rebecca Dent…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:34

    Published on:

  25. Content type: Research article

    Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and...

    Authors: Juan J. Miret, Paul Kirschmeier, Shohei Koyama, Mingrui Zhu, Yvonne Y. Li, Yujiro Naito, Min Wu, Venkat S. Malladi, Wei Huang, William Walker, Sangeetha Palakurthi, Glenn Dranoff, Peter S. Hammerman, Chad V. Pecot, Kwok-Kin Wong and Esra A. Akbay

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:32

    Published on:

  26. Content type: Research article

    Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunothe...

    Authors: Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B. Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:29

    Published on:

  27. Content type: Research article

    Tumor specific Th9 cells are potential effector cells for adoptive therapy of human cancers. TNF family members OX40L, TL1A and GITRL have been shown to promote the induction of Th9 cells and antitumor immunit...

    Authors: Yuxue Jiang, Jintong Chen, Enguang Bi, Yinghua Zhao, Tianxue Qin, Yiming Wang, Alison Wang, Sujun Gao, Qing Yi and Siqing Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:28

    Published on:

  28. Content type: Research article

    The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer va...

    Authors: Elham Beyranvand Nejad, Robert B. Ratts, Eleni Panagioti, Christine Meyer, Jennifer D. Oduro, Luka Cicin-Sain, Klaus Früh, Sjoerd H. van der Burg and Ramon Arens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:25

    Published on:

  29. Content type: Research article

    Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a n...

    Authors: Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:16

    Published on:

  30. Content type: Research article

    Regulatory T cells (Tregs) may comprise different subsets allowing them to efficiently suppress different types of effector T cells. In this study, we show that high numbers of both conventional and Tbet co-ex...

    Authors: S. J. Santegoets, C. L. Duurland, E. S. Jordanova, J. J. van Ham, I. Ehsan, S. L. van Egmond, M. J. P. Welters and S. H. van der Burg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:14

    Published on:

  31. Content type: Research article

    The tumor microenvironment (TME) is a complex mixture of tumor epithelium, stroma and immune cells, and the immune component of the TME is highly prognostic for tumor progression and patient outcome. In lung c...

    Authors: Katey S. S. Enfield, Spencer D. Martin, Erin A. Marshall, Sonia H. Y. Kung, Paul Gallagher, Katy Milne, Zhaoyang Chen, Brad H. Nelson, Stephen Lam, John C. English, Calum E. MacAulay, Wan L. Lam and Martial Guillaud

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:13

    Published on:

  32. Content type: Research article

    Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response. However,...

    Authors: Aurelie Hanoteau, Jared M. Newton, Rosemarie Krupar, Chen Huang, Hsuan-Chen Liu, Angelina Gaspero, Robyn D. Gartrell, Yvonne M. Saenger, Thomas D. Hart, Saskia J. Santegoets, Damya Laoui, Chad Spanos, Falguni Parikh, Padmini Jayaraman, Bing Zhang, Sjoerd H. Van der Burg…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:10

    Published on:

  33. Content type: Research article

    Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonis...

    Authors: Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig and Manuel Schmidt

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:5

    Published on:

  34. Content type: Research article

    PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune syste...

    Authors: Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson and Simon T. Barry

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:158

    Published on:

  35. Content type: Research article

    Tumor-associated macrophages (TAMs) facilitate tumor progression via establishment of an immunosuppressive tumor microenvironment (TME). However, it is poorly understood how tumor cells could functionally modu...

    Authors: Zhi-Fa Wen, Hongxiang Liu, Rong Gao, Meng Zhou, Jie Ma, Yue Zhang, Jinjin Zhao, Yongqiang Chen, Tianyu Zhang, Fang Huang, Ning Pan, Jinping Zhang, Bernard A. Fox, Hong-Ming Hu and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:151

    Published on:

  36. Content type: Research article

    Tumor cell mediated immune-suppression remains a question of interest in tumor biology. In this study, we focused on the metabolites that are released by prostate cancer cells (PCC), which could potentially at...

    Authors: Yutao Yan, Lei Chang, Hongzhe Tian, Lu Wang, Yawei Zhang, Tao Yang, Guohao Li, Weifeng Hu, Kavita Shah, Gang Chen and Yonglian Guo

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:148

    Published on:

  37. Content type: Research article

    Ligands for the Toll-like receptor (TLR) family can induce activation of cells of the innate immune system and are widely studied for their potential to enhance adaptive immunity. Conjugation of TLR2-ligand Pa...

    Authors: Gijs G. Zom, Marian M. J. H. P. Willems, Selina Khan, Tetje C. van der Sluis, Jan Willem Kleinovink, Marcel G. M. Camps, Gijsbert A. van der Marel, Dmitri V. Filippov, Cornelis J. M. Melief and Ferry Ossendorp

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:146

    Published on:

  38. Content type: Research article

    Regulatory B (Breg) cells represent one of the B cell subsets that infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the phenotype, function and clinical re...

    Authors: Linsen Ye, Qi Zhang, Yusheng Cheng, Xiaolong Chen, Guoying Wang, Mengchen Shi, Tong Zhang, Yingjiao Cao, Hang Pan, Liting Zhang, Genshu Wang, Yinan Deng, Yang Yang and Guihua Chen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:145

    Published on:

  39. Content type: Research article

    T lymphocytes and HLA expression on tumor cell both influence prognostic of localized colorectal cancer, but their role following chemotherapy in patients with liver metastatic colorectal cancer (mCRC) was not...

    Authors: Fanny Ledys, Quentin Klopfenstein, Caroline Truntzer, Laurent Arnould, Julie Vincent, Leila Bengrine, Romain Remark, Romain Boidot, Sylvain Ladoire, Francois Ghiringhelli and Valentin Derangere

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:123

    Published on:

  40. Content type: Research article

    Women diagnosed with breast cancer within 5 years postpartum (PPBC) have poorer prognosis than age matched nulliparous women, even after controlling for clinical variables known to impact disease outcomes. Thr...

    Authors: Nathan D. Pennock, Holly A. Martinson, Qiuchen Guo, Courtney B. Betts, Sonali Jindal, Takahiro Tsujikawa, Lisa M. Coussens, Virginia F. Borges and Pepper Schedin

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:98

    Published on:

  41. Content type: Research article

    Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the ...

    Authors: Guozhu Xie, Tan Cheng, Jie Lin, Lanfang Zhang, Jieling Zheng, Ying Liu, Guobo Xie, Baiyao Wang and Yawei Yuan

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:88

    Published on:

  42. Content type: Commentary

    Immunotherapy is rapidly becoming the fourth arm of cancer treatment, and breakthrough successes have been observed in multiple malignancies. However, despite the potential for impressive anti-tumor effects, o...

    Authors: Robert J. Canter and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:79

    Published on:

  43. Content type: Research article

    Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are attractive targets for TCR gene therapy of cancer. The majority of such mutations are patient-sp...

    Authors: Vanessa M. Tubb, Deborah S. Schrikkema, Nathan P. Croft, Anthony W. Purcell, Carsten Linnemann, Manon R. Freriks, Frederick Chen, Heather M. Long, Steven P. Lee and Gavin M. Bendle

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:70

    Published on:

  44. Content type: Short report

    Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the...

    Authors: Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell and Carolina S. Ilkow

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:62

    Published on:

  45. Content type: Research article

    The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor t...

    Authors: Edwin R. Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G. Swisher, William N. William Jr, Jiexin Zhang, Jack Lee, Tina Cascone, John V. Heymach, Marie-Andrée Forget, Cara Haymaker, Chantale Bernatchez, Neda Kalhor, Annikka Weissferdt…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:48

    Published on:

  46. Content type: Research article

    Receptors specific for the sugar N-acetylgalactosamine (GalNAc) include the human type II, C-type lectin receptor macrophage galactose-type lectin/C-type lectin receptor family member 10A (MGL/CLEC10A/CD301) that...

    Authors: Laura L. Eggink, Katherine F. Roby, Robert Cote and J. Kenneth Hoober

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:28

    Published on:

  47. Content type: Research article

    Numerous oncology combination therapies involving modulators of the cancer immune cycle are being developed, yet quantitative simulation models predictive of outcome are lacking. We here present a model-based ...

    Authors: Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski and Gabriel Helmlinger

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:17

    Published on:

  48. Content type: Research article

    Immuno-oncotherapy has emerged as a promising means to target cancer. In particular, therapeutic manipulation of tumor-associated macrophages holds promise due to their various and sometimes opposing roles in ...

    Authors: Grace Mahlbacher, Louis T. Curtis, John Lowengrub and Hermann B. Frieboes

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:10

    Published on:

  49. Content type: Research article

    Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion. Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads t...

    Authors: Susanne M. Steggerda, Mark K. Bennett, Jason Chen, Ethan Emberley, Tony Huang, Julie R. Janes, Weiqun Li, Andrew L. MacKinnon, Amani Makkouk, Gisele Marguier, Peter J. Murray, Silinda Neou, Alison Pan, Francesco Parlati, Mirna L. M. Rodriguez, Lee-Ann Van de Velde…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:101

    Published on:

  50. Content type: Research article

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...

    Authors: Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:64

    Published on:

Annual Journal Metrics

Advertisement